Rigel Pharmaceuticals (RIGL) Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.

Which has stronger earnings & valuation, RIGL or GTHX?

Rigel Pharmaceuticals has higher revenue and earnings than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$116.88M	3.63	-$25.09M	$0.14	172.16
G1 Therapeutics	$58.20M	6.42	-$47.97M	-$0.62	-11.53

Do analysts recommend RIGL or GTHX?

Rigel Pharmaceuticals currently has a consensus price target of $31.30, suggesting a potential upside of 29.88%. G1 Therapeutics has a consensus price target of $4.00, suggesting a potential downside of 44.06%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rigel Pharmaceuticals is more favorable than G1 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
G1 Therapeutics	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do institutionals & insiders have more ownership in RIGL or GTHX?

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of G1 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is RIGL or GTHX more profitable?

Rigel Pharmaceuticals has a net margin of 2.46% compared to G1 Therapeutics' net margin of -76.93%. Rigel Pharmaceuticals' return on equity of -14.80% beat G1 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	2.46%	-14.80%	3.03%
G1 Therapeutics	-76.93%	-136.98%	-39.33%

Which has more risk and volatility, RIGL or GTHX?

Rigel Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Does the media favor RIGL or GTHX?

In the previous week, Rigel Pharmaceuticals had 13 more articles in the media than G1 Therapeutics. MarketBeat recorded 13 mentions for Rigel Pharmaceuticals and 0 mentions for G1 Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.68 beat G1 Therapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Positive
G1 Therapeutics	Neutral

Does the MarketBeat Community believe in RIGL or GTHX?

Rigel Pharmaceuticals received 146 more outperform votes than G1 Therapeutics when rated by MarketBeat users. Likewise, 68.97% of users gave Rigel Pharmaceuticals an outperform vote while only 65.97% of users gave G1 Therapeutics an outperform vote.

Company	Underperform	Outperform
Rigel Pharmaceuticals	Outperform Votes 460 68.97%	Underperform Votes 207 31.03%
G1 Therapeutics	Outperform Votes 314 65.97%	Underperform Votes 162 34.03%

Summary

Rigel Pharmaceuticals beats G1 Therapeutics on 16 of the 18 factors compared between the two stocks.